Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer. Reply.

Bardia A, Mayer IA, Kalinsky K.

N Engl J Med. 2019 Jun 13;380(24):2382. doi: 10.1056/NEJMc1903943. No abstract available.

PMID:
31189049
2.

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.

Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D.

N Engl J Med. 2019 Jun 4. doi: 10.1056/NEJMoa1903765. [Epub ahead of print]

PMID:
31166679
3.

Comment on 'Bullous pyoderma gangrenosum secondary to underlying multiple myeloma: treated with ciclosporin'.

Rajan MB, Singh S, Bardia A, Nalwa A.

Clin Exp Dermatol. 2019 Jun 4. doi: 10.1111/ced.14019. [Epub ahead of print]

PMID:
31162845
4.

Engineering bio-mimetic humanized neurological constructs using acellularized scaffolds of cryopreserved meningeal tissues.

Vishwakarma SK, Lakkireddy C, Bardia A, Paspala SAB, Khan AA.

Mater Sci Eng C Mater Biol Appl. 2019 Sep;102:34-44. doi: 10.1016/j.msec.2019.04.028. Epub 2019 Apr 12.

PMID:
31147006
5.

Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.

Sheng JY, Blackford AL, Bardia A, Venkat R, Rosson G, Giles J, Hayes DF, Jeter SC, Zhang Z, Hayden J, Nguyen A, Storniolo AM, Tarpinian K, Henry NL, Stearns V.

Breast Cancer Res Treat. 2019 May 11. doi: 10.1007/s10549-019-05270-4. [Epub ahead of print]

PMID:
31079282
6.

Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer.

Wander SA, Spring LM, Bardia A.

Lancet Oncol. 2019 Jun;20(6):746-748. doi: 10.1016/S1470-2045(19)30279-7. Epub 2019 Apr 27. No abstract available.

PMID:
31036469
7.

Clinical Validation of a Cell-Free DNA Gene Panel.

Cheng J, Cao Y, MacLeay A, Lennerz JK, Baig A, Frazier RP, Lee J, Hu K, Pacula M, Meneses E, Robinson H, Batten JM, Brastianos PK, Heist RS, Bardia A, Le LP, Iafrate AJ.

J Mol Diagn. 2019 Apr 23. pii: S1525-1578(18)30562-2. doi: 10.1016/j.jmoldx.2019.02.008. [Epub ahead of print]

PMID:
31026600
8.

Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer.

Daniell KM, Bardia A, Sun F, Roberts SA, Brunelle CL, Gillespie TC, Sayegh HE, Naoum GE, Juric D, Isakoff SJ, Fitzgerald DM, Taghian AG.

Breast Cancer Res Treat. 2019 Jun;175(3):649-658. doi: 10.1007/s10549-019-05206-y. Epub 2019 Mar 27.

PMID:
30919166
9.

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.

Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O'Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL.

Nat Commun. 2019 Mar 26;10(1):1373. doi: 10.1038/s41467-019-09068-2.

10.

Preoperative chlorhexidine mouthwash to reduce pneumonia after cardiac surgery: A systematic review and meta-analysis.

Bardia A, Blitz D, Dai F, Hersey D, Jinadasa S, Tickoo M, Schonberger RB.

J Thorac Cardiovasc Surg. 2019 Jan 21. pii: S0022-5223(19)30066-2. doi: 10.1016/j.jtcvs.2019.01.014. [Epub ahead of print]

PMID:
30826096
11.

Intraperitoneal transplantation of bioengineered humanized liver grafts supports failing liver in acute condition.

Vishwakarma SK, Bardia A, Lakkireddy C, Raju N, Paspala SAB, Habeeb MA, Khan AA.

Mater Sci Eng C Mater Biol Appl. 2019 May;98:861-873. doi: 10.1016/j.msec.2019.01.045. Epub 2019 Jan 14.

PMID:
30813092
12.

CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions.

Spring LM, Wander SA, Zangardi M, Bardia A.

Curr Oncol Rep. 2019 Feb 26;21(3):25. doi: 10.1007/s11912-019-0769-3. Review.

PMID:
30806829
13.

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K.

N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213.

PMID:
30786188
14.

Correction: 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA.

Clin Cancer Res. 2019 Feb 15;25(4):1435. doi: 10.1158/1078-0432.CCR-18-4266. No abstract available.

PMID:
30770494
15.

Pigmented nipple-like nodule on the neck.

Mushtaq S, Singh S, Khera S, Bardia A.

Indian J Dermatol Venereol Leprol. 2019 Mar-Apr;85(2):235. doi: 10.4103/ijdvl.IJDVL_345_18. No abstract available.

16.

Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models.

Keklikoglou I, Cianciaruso C, Güç E, Squadrito ML, Spring LM, Tazzyman S, Lambein L, Poissonnier A, Ferraro GB, Baer C, Cassará A, Guichard A, Iruela-Arispe ML, Lewis CE, Coussens LM, Bardia A, Jain RK, Pollard JW, De Palma M.

Nat Cell Biol. 2019 Feb;21(2):190-202. doi: 10.1038/s41556-018-0256-3. Epub 2018 Dec 31.

PMID:
30598531
17.

Bioengineered functional humanized livers: An emerging supportive modality to bridge the gap of organ transplantation for management of end-stage liver diseases.

Vishwakarma SK, Lakkireddy C, Bardia A, Paspala SAB, Tripura C, Habeeb MA, Khan AA.

World J Hepatol. 2018 Nov 27;10(11):822-836. doi: 10.4254/wjh.v10.i11.822. Review.

18.

Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications.

Bardia A, Wai M, Fontes ML.

Curr Opin Anaesthesiol. 2019 Feb;32(1):80-85. doi: 10.1097/ACO.0000000000000674. Review.

PMID:
30531609
19.

Sacituzumab for the treatment of triple-negative breast cancer: the poster child of future therapy?

Zangardi ML, Spring LM, Nagayama A, Bardia A.

Expert Opin Investig Drugs. 2019 Feb;28(2):107-112. doi: 10.1080/13543784.2019.1555239. Epub 2018 Dec 17. Review.

PMID:
30507322
20.

Bioengineering Human Neurological Constructs Using Decellularized Meningeal Scaffolds for Application in Spinal Cord Injury.

Vishwakarma SK, Bardia A, Lakkireddy C, Paspala SAB, Khan AA.

Front Bioeng Biotechnol. 2018 Nov 1;6:150. doi: 10.3389/fbioe.2018.00150. eCollection 2018.

21.

Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer.

Bardia A, Hovnanian MD, Brachtel EF, Nardi V.

N Engl J Med. 2018 Nov 15;379(20):1946-1953. doi: 10.1056/NEJMcpc1616400. No abstract available.

PMID:
30428289
22.

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

Slavin TP, Banks KC, Chudova D, Oxnard GR, Odegaard JI, Nagy RJ, Tsang KWK, Neuhausen SL, Gray SW, Cristofanilli M, Rodriguez AA, Bardia A, Leyland-Jones B, Janicek MF, Lilly M, Sonpavde G, Lee CE, Lanman RB, Meric-Bernstam F, Kurzrock R, Weitzel JN.

J Clin Oncol. 2018 Oct 19:JCO1800328. doi: 10.1200/JCO.18.00328. [Epub ahead of print]

PMID:
30339520
23.

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

Bardia A, Parton M, Kümmel S, Estévez LG, Huang CS, Cortés J, Ruiz-Borrego M, Telli ML, Martin-Martorell P, López R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz SA, Mayer IA, Carreon D, Cameron S, Liao S, Baselga J, Kim SB.

J Clin Oncol. 2018 Sep 20:JCO2017748392. doi: 10.1200/JCO.2017.74.8392. [Epub ahead of print]

PMID:
30235087
24.

Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.

Spring L, Niemierko A, Haddad S, Yuen M, Comander A, Reynolds K, Shin J, Bahn A, Brachtel E, Specht M, Smith BL, Taghian A, Jimenez R, Peppercorn J, Isakoff SJ, Moy B, Bardia A.

Breast Cancer Res Treat. 2018 Dec;172(3):733-740. doi: 10.1007/s10549-018-4959-8. Epub 2018 Sep 15.

PMID:
30220055
25.

Molecular dynamics of pancreatic transcription factors in bioengineered humanized insulin producing neoorgan.

Vishwakarma SK, Lakkireddy C, Bardia A, Raju N, Paspala SAB, Habeeb MA, Khan AA.

Gene. 2018 Oct 30;675:165-175. doi: 10.1016/j.gene.2018.07.006. Epub 2018 Jul 3.

PMID:
30180963
26.

Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer.

Princic N, Aizer A, Tang DH, Smith DM, Johnson W, Bardia A.

Curr Med Res Opin. 2018 Sep 20:1-8. doi: 10.1080/03007995.2018.1519500. [Epub ahead of print]

PMID:
30175631
27.

A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer.

Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, Toner M, Haber DA, Maheswaran S.

Cancer Discov. 2018 Oct;8(10):1286-1299. doi: 10.1158/2159-8290.CD-18-0432. Epub 2018 Aug 13.

PMID:
30104333
28.

Protective Role of Hypothermia Against Heat Stress in Differentiated and Undifferentiated Human Neural Precursor Cells: A Differential Approach for the Treatment of Traumatic Brain Injury.

Vishwakarma SK, Bardia A, Fathima N, Chandrakala L, Rahamathulla S, Raju N, Srinivas G, Raj A, Sandhya A, Satti V, Tiwari SK, Paspala SAB, Khan AA.

Basic Clin Neurosci. 2017 Nov-Dec;8(6):453-466. doi: 10.29252/NIRP.BCN.8.6.453.

29.

Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances.

Bardia A, Hurvitz S.

Clin Cancer Res. 2018 Nov 1;24(21):5206-5218. doi: 10.1158/1078-0432.CCR-18-0162. Epub 2018 Jun 8. Review.

PMID:
29884743
30.

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS.

Lancet Oncol. 2018 Jul;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4. Epub 2018 May 24.

PMID:
29804902
31.

Research Biopsies: An Integrative Review of the Experiences of Patients With Cancer.

Abraham E, Post K, Spring L, Malvarosa G, Tripp E, Peppercorn JM, Bardia A, Habin K.

Clin J Oncol Nurs. 2018 Jun 1;22(3):E71-E77. doi: 10.1188/18.CJON.E71-E77. Review.

PMID:
29781452
32.

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.

Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU.

NPJ Breast Cancer. 2018 May 4;4:10. doi: 10.1038/s41523-018-0060-z. eCollection 2018.

33.

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.

Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V.

Breast Cancer Res Treat. 2018 Aug;171(1):121-129. doi: 10.1007/s10549-018-4811-1. Epub 2018 May 11.

34.

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.

Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA.

Breast Cancer Res Treat. 2018 Aug;171(1):111-120. doi: 10.1007/s10549-018-4813-z. Epub 2018 May 9.

PMID:
29744674
35.

Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer.

Spring L, Bardia A.

Clin Cancer Res. 2018 Jul 1;24(13):2981-2983. doi: 10.1158/1078-0432.CCR-18-0463. Epub 2018 Apr 23.

PMID:
29685881
36.

Role of drug transporters and heat shock proteins during ethanol exposure to human neural precursor cells and its lineages.

Vishwakarma SK, Fatima N, Lakkireddy C, Raju N, Bardia A, Sandhya A, Paspala SAB, Satti V, Khan AA.

Tissue Cell. 2018 Apr;51:14-23. doi: 10.1016/j.tice.2018.02.001. Epub 2018 Feb 7.

PMID:
29622083
37.

AR Expression in Breast Cancer CTCs Associates with Bone Metastases.

Aceto N, Bardia A, Wittner BS, Donaldson MC, O'Keefe R, Engstrom A, Bersani F, Zheng Y, Comaills V, Niederhoffer K, Zhu H, Mackenzie O, Shioda T, Sgroi D, Kapur R, Ting DT, Moy B, Ramaswamy S, Toner M, Haber DA, Maheswaran S.

Mol Cancer Res. 2018 Apr;16(4):720-727. doi: 10.1158/1541-7786.MCR-17-0480. Epub 2018 Feb 16.

38.

Bioengineered humanized livers as better three-dimensional drug testing model system.

Vishwakarma SK, Bardia A, Lakkireddy C, Nagarapu R, Habeeb MA, Khan AA.

World J Hepatol. 2018 Jan 27;10(1):22-33. doi: 10.4254/wjh.v10.i1.22.

39.

Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology.

Vidula N, Bardia A.

Oncotarget. 2017 Nov 21;8(63):106167-106168. doi: 10.18632/oncotarget.22580. eCollection 2017 Dec 5. No abstract available.

40.

Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO) in Adult Patients - Many Questions, Few Answers, and Hard Choices.

Bardia A, Schonberger RB.

J Cardiothorac Vasc Anesth. 2018 Jun;32(3):1183-1184. doi: 10.1053/j.jvca.2017.10.037. Epub 2017 Oct 31. No abstract available.

PMID:
29276089
41.

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.

Cancer Discov. 2018 Mar;8(3):336-353. doi: 10.1158/2159-8290.CD-17-0535. Epub 2017 Dec 14.

42.

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.

Condorelli R, Spring L, O'Shaughnessy J, Lacroix L, Bailleux C, Scott V, Dubois J, Nagy RJ, Lanman RB, Iafrate AJ, Andre F, Bardia A.

Ann Oncol. 2018 Mar 1;29(3):640-645. doi: 10.1093/annonc/mdx784.

PMID:
29236940
43.

Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.

Nagayama A, Ellisen LW, Chabner B, Bardia A.

Target Oncol. 2017 Dec;12(6):719-739. doi: 10.1007/s11523-017-0535-0. Review.

PMID:
29116596
44.

Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.

Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A.

J Natl Compr Canc Netw. 2017 Oct;15(10):1216-1223. doi: 10.6004/jnccn.2017.0158.

PMID:
28982747
45.

Enhanced neuroprotective effect of mild-hypothermia with VPA against ethanol-mediated neuronal injury.

Vishwakarma SK, Bardia A, Chandrakala L, Arshiya S, Paspala SAB, Satti V, Khan AA.

Tissue Cell. 2017 Dec;49(6):638-647. doi: 10.1016/j.tice.2017.09.004. Epub 2017 Sep 14.

PMID:
28947065
46.

Mechanism of Action and Clinical Impact of Ribociclib-Response.

Tripathy D, Bardia A, Sellers WR.

Clin Cancer Res. 2017 Sep 15;23(18):5658. doi: 10.1158/1078-0432.CCR-17-1819. No abstract available.

47.

Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.

Zangardi ML, Spring LM, Blouin GC, Bardia A.

Expert Rev Clin Pharmacol. 2017 Nov;10(11):1169-1176. doi: 10.1080/17512433.2017.1376653. Epub 2017 Sep 18. Review.

PMID:
28875723
48.

Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells.

Vishwakarma SK, Sharmila P, Bardia A, Chandrakala L, Raju N, Sravani G, Sastry BVS, Habeeb MA, Khan AA, Dhayal M.

Sci Rep. 2017 Aug 17;7(1):8539. doi: 10.1038/s41598-017-08878-y.

49.

AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer.

Kabraji S, Solé X, Huang Y, Bango C, Bowden M, Bardia A, Sgroi D, Loda M, Ramaswamy S.

Breast Cancer Res. 2017 Aug 1;19(1):88. doi: 10.1186/s13058-017-0877-7.

50.

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.

Spring LM, Zangardi ML, Moy B, Bardia A.

Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634/theoncologist.2017-0142. Epub 2017 Jul 13. Review.

Supplemental Content

Loading ...
Support Center